Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.25.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following is a summary of awards outstanding as of September 30, 2025 and 2024, which are not included in the computation of basic and diluted weighted average shares:

 

 

Three and nine months ended
September 30,

 

 

2025

 

 

2024

 

Stock options (excluding exercisable penny stock options)

 

 

8,912,143

 

 

 

7,244,175

 

Restricted stock units

 

 

519,947

 

 

 

283,411

 

Warrants

 

 

5,827,035

 

 

 

5,152,397

 

Total

 

 

15,259,125

 

 

 

12,679,983

 

Schedule of Segment Reporting Information, by Segment In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:

 

 

Three months ended September 30,

 

 

Nine months ended September 30,

 

(in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Employee expenses

 

$

2,949

 

 

$

2,469

 

 

$

8,821

 

 

$

7,351

 

Research and Development (excluding employee expenses):

 

 

 

 

 

 

 

 

 

 

 

 

Consulting and professional fees

 

 

546

 

 

 

1,106

 

 

 

1,220

 

 

 

2,525

 

Clinical study expenses

 

 

92

 

 

 

127

 

 

 

297

 

 

 

901

 

Product development

 

 

677

 

 

 

324

 

 

 

2,032

 

 

 

883

 

Other*

 

 

313

 

 

 

189

 

 

 

951

 

 

 

659

 

Total Research and development expense

 

$

1,628

 

 

$

1,746

 

 

$

4,500

 

 

$

4,968

 

General and administrative expense (excluding employee expenses):

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative expenses

 

 

477

 

 

 

683

 

 

 

1,804

 

 

 

2,213

 

Commercialization readiness expenses

 

 

236

 

 

 

171

 

 

 

704

 

 

 

411

 

Total General and administrative expense

 

 

713

 

 

 

854

 

 

 

2,508

 

 

 

2,624

 

Total operating expenses

 

$

5,290

 

 

$

5,069

 

 

$

15,829

 

 

$

14,943

 

 

* Other primarily includes patent, and testing for three and nine months ended September 30, 2025 and 2024.